Target Name: ELAVL3
NCBI ID: G1995
Review Report on ELAVL3 Target / Biomarker Content of Review Report on ELAVL3 Target / Biomarker
ELAVL3
Other Name(s): ELAV like RNA binding protein 3, transcript variant 2 | paraneoplastic cerebellar degeneration-associated antigen | ELAV like neuron-specific RNA binding protein 3 | Hu antigen C | ELAV-like protein 3 (isoform 2) | ELAV-like protein 3 | DKFZp547J036 | ELAVL3 variant 2 | ELAV-like 3 | MGC20653 | ELAV3_HUMAN | HUC | ELAV like RNA binding protein 3, transcript variant 1 | ELAVL3 variant 1 | HUCL | HuC | ELAV-like protein 3 (isoform 1) | hu-antigen C | PLE21 | Paraneoplastic cerebellar degeneration-associated antigen | ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C) | Hu-antigen C | ELAV like RNA binding protein 3 | paraneoplastic limbic encephalitis antigen 21 | Paraneoplastic limbic encephalitis antigen 21

ELAVL3: A Potential Drug Target and Biomarker

ELAVL3, a gene that encodes a protein known as ECT-2, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make it an intriguing target for researchers to explore.

The ECT-2 protein is a key regulator of the cell cycle and has been shown to play a crucial role in various cellular processes, including cell division, apoptosis, and angiogenesis. It is expressed in various tissues and cells throughout the body and has been implicated in the development and progression of many diseases.

ELAVL3 has been identified as a potential drug target due to its unique expression patterns and its involvement in various cellular processes that are linked to the development of many diseases. Studies have shown that high levels of ELAVL3 expression are associated with the development of cancer, neurodegenerative disorders, and autoimmune diseases.

One of the most significant findings related to ELAVL3 is its involvement in the development of cancer. Many studies have shown that high levels of ELAVL3 expression are associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. This is because ELAVL3 has been shown to regulate the cell cycle, which is a critical step in the development of cancer cells.

Another potential mechanism by which ELAVL3 may contribute to the development of cancer is its role in apoptosis, which is the process by which cells undergo programmed cell death. Studies have shown that ELAVL3 plays a crucial role in regulating apoptosis and that high levels of ELAVL3 expression are associated with an increased risk of apoptosis.

ELAVL3 has also been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and can lead to a wide range of symptoms, including memory loss, tremors, and difficulty with movement.

Studies have shown that ELAVL3 is expressed in the brains of individuals with Alzheimer's disease and that high levels of ELAVL3 expression are associated with the development of this disease. Additionally, ELAVL3 has been shown to play a role in the development of Parkinson's disease, a similar disorder that is characterized by the progressive loss of brain cells.

Finally, ELAVL3 has also been implicated in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These disorders are characterized by an overreactive immune system that can cause inflammation and damage to various body parts.

Studies have shown that ELAVL3 is expressed in the brains of individuals with rheumatoid arthritis and that high levels of ELAVL3 expression are associated with the development of this disease. Additionally, ELAVL3 has been shown to play a role in the development of multiple sclerosis, a similar disorder that is characterized by inflammation and damage to the central nervous system.

In conclusion, ELAVL3 is a gene that has been identified as a potential drug target and biomarker for a wide range of diseases. Its unique structure and function make it an intriguing target for researchers to explore. Further studies are needed to fully understand the role of ELAVL3 in the development and progression of these diseases.

Protein Name: ELAV Like RNA Binding Protein 3

Functions: RNA-binding protein that binds to AU-rich element (ARE) sequences of target mRNAs, including VEGF mRNA (PubMed:10710437). May also bind poly-A tracts via RRM 3 (By similarity). May be involved in neuronal differentiation and maintenance (By similarity). Plays a role in the stabilization of GAP43 mRNA and in spatial learning (By similarity)

The "ELAVL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELAVL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK)